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Cardiovascular Disease
in Tetralogy of Fallot
Patients >50 Years of AgeAcquired cardiovascular diseases, such as coronary
artery disease (CAD) and cerebrovascular accident
(CVA) or transient ischemic attack (TIA), were
reported main determinants of mortality in elderly
patients with mainly anatomically classified simple
congenital heart disease (CHD) (1,2). However,
whether this is similar in patients born with severe
cyanotic lesions remains unknown. Patients with
tetralogy of Fallot (TOF) are the first specific group
with cyanotic CHD, on average reaching >50 years of
age (3). We sought to determine the role of acquired
cardiovascular disease in mortality and morbidity of
elderly TOF patients.
Out of 794 adult TOF patients within 6 partici-
pating centers in the prospective Dutch nationwide
CONCOR (Congenital Corvitia) registry, a total of 167
patients >50 years of age were included (55% men,
40% previous shunt, 32% >18 years of age at correc-
tion, 42% previous sustained ventricular tachycardia,
11% previous ventricular tachycardia, 25% previous
pulmonary valve replacement, 7% previous CVA or
TIA, 2% previous CAD, QRS duration 150  27 ms).
Follow-up (6.4  3.8 years) started at CONCOR reg-
istry inclusion (n ¼ 65, age >50 years) or at the
50th birthday (n ¼ 102, 50th birthday after CONCOR
registry inclusion). Mortality was compared to a
reference cohort (100:1 TOF patient) of age- and
gender-matched Dutch inhabitants using data from
the Dutch Central Bureau of Statistics.
TOF patients had an increased mortality risk
compared to the reference cohort (hazard ratio: 3.11;
95% confidence interval: 2.04 to 4.73) (Figure 1A).
There was a cardiovascular cause of death in 64%
(14 of 22) patients (heart failure: 12, sudden cardiac
death: 1, CVA: 1) versus 20% in a comparable Dutch
population. Heart failure progression was observed
in 24 patients (11 right ventricular failure, 11 right
ventricular þ left ventricular failure, 2 left
ventricular failure). Furthermore, 11 patients hadCAD (2 coronary revascularization, 3 myocardial
infarction, 6 stable CAD) and 8 patients had CVA
(n ¼ 4) or TIA (n ¼ 4) during follow-up. CVA or TIA
was more prevalent than expected (n ¼ 4.6), while
myocardial infarction occurred at the expected rate.
Only 4 patients had VT during follow-up. The
estimated yearly risk of heart failure increased from
0.8% per year in patients 50 years of age to 5.7% in
patients 70 years of age (Figure 1B). The risk of
acquired cardiovascular disease (CAD and CVA or
TIA) was substantially lower but also increased
yearly (from 0.5% and 0.4% at 50 years of age to
2.1% and 1.5% at 70 years of age, respectively). The
estimated yearly risk of all morbidity or mortality
increased to 10.5% (95% confidence interval: 6.7% to
16.4%) at 70 years of age (Figure 1B).
The present study demonstrated a markedly
increased mortality of TOF patients, after reaching
the 50th birthday. Heart failure was the cause of
death in 55%, likely attributed to TOF-related factors.
This is in line with TOF patients from other age
categories but in contrast with previous studies
focusing on elderly CHD patients, which found ac-
quired cardiovascular diseases as main determinants
of mortality in elderly (mainly non-severe) CHD
patients (1–3). Presumably due to residual lesions and
longstanding childhood cyanosis in TOF, heart failure
outweighs typical acquired cardiovascular diseases
throughout late follow-up. The rate of myocardial
infarction was similar to the general population. CVA/
TIA, which were approximately 2-fold increased, may
be attributed to both TOF-related factors such as re-
sidual septal defects or supraventricular arrhythmias,
and acquired cardiovascular disease.
This study is limited by its design; a retrospective
analysis of patients enrolled in a prospective registry
Advantages include the large, multicenter nature of
the registry with inclusive enrollment at each site
(which may reduce selection bias) and prospective
follow-up data. However, data were retrospectively
acquired and outcomes could be missed if not noted in
hospital database or CONCOR registry. The results are
applicable to late survivors of TOF born before 1965.
Currently, most children are operated on earlier with
altered techniques.
In conclusion, TOF patients >50 years of age had an
approximately 3-fold higher mortality risk compared









Hazard ratio TOF 3.11 (95% CI: 2.04-4.73)
































(A) Overall survival in tetralogy of Fallot (TOF) versus Dutch reference population. Survival curves were created using a delayed entry method with age as time scale for
left-truncated, right-censored data to display overall survival of TOF patients compared to the matched (1:100) Dutch reference cohort. (B) Estimated yearly risk of
cardiovascular disease in tetralogy of Fallot. Estimated yearly risk of cardiovascular disease with age as time scale using smoothed estimates based on B-splines
(bshazard package, R Project for Statistical Computing, Vienna, Austria). CAD ¼ coronary artery disease; CVA ¼ cerebrovascular accident; TIA ¼ transient ischemic
attack; VT ¼ ventricular tachycardia.
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2466to the general population. Acquired cardiovascular
diseases such as myocardial infarction and CVA had a
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in Patients With Dilated
CardiomyopathyDilated cardiomyopathy (DCM) has a population
prevalence of w1 in 500 and is associated with prog-
nostically adverse arrhythmias at initial disease pre-
sentation in up to one-third of patients (1). While
